TransCode Therapeutics, Inc.

Stocks

RNAZ

US89357L5012

Delayed Nasdaq Other stock markets 21:08:13 24/06/2026 +03			5-day change	1st Jan Change
4.820 ^USD	-0.72%		-9.91%	-29.43%

06-18	TransCode Therapeutics, Inc. - Special Call
06-03	TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a	MT

Transcript : TransCode Therapeutics, Inc. - Special Call

Published on 06/18/2026 at 07:20 pm +03 - Modified on 06/18/2026 at 08:20 pm +03

S&P Capital IQ

Presenter Speech
Philippe Calais (Executives)

Good morning, everyone, and thank you very much for joining us for this first ever webcast to cover our company research and corporate strategy. I'm

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about TransCode Therapeutics, Inc.

06-18	TransCode Therapeutics, Inc. - Special Call
06-03	TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a	MT
06-03	Transcode Therapeutics Completes Phase 1A Clinical Trial and Advances Ttx-Mc138 to Phase 2A Development	CI
05-27	TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 In Patients With ctDNA Positive Colorectal Cancer	CI
05-15	TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-01	TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal	MT
04-27	Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board	RE
04-27	TransCode Therapeutics, Inc. Appoints Anna Moore as Chair of Scientific Advisory Board	CI
04-15	TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	TransCode Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-06	TransCode Therapeutics, Inc. announced that it expects to receive $19.7 million in funding from Yorkville Advisors Global LP	CI
03-03	Transcode Therapeutics, Inc. and Unleash Immuno Oncolytics, Inc. Secure Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement	CI
03-03	TransCode Therapeutics Inc - enters exclusive license agreement with Unleash	RE
02-23	TransCode Therapeutics, Inc. Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development	CI
02-06	TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Announce Submission of Ind Amendment for Phase 2A Clinical Trial Withttx-Mc138	CI